1

TAVANIC

levofloxacin

2

Mode Of Action

Rapid bactericidal action:

inhibits DNA gyrase (resealing)

inhibits topoisomerase IV

(no separation of interlinked daughter DNA molecules)

3

Pharmacokinetics

Rapid, complete absorption after oral administration

100% bioavailable

T-max : 1 hour

IV and oral formulations are bioequivalent switch /

sequential therapy

Minimal hepatic metabolism; 2 metabolites identified in

urine (<5% of total Levofloxacin)

Half life is 6 – 8 hours

once daily dosage

6

Indications

GRAM-POSITIVE GRAM-NEGATIVE

S. pneumoniae

S. aureus ***

M. catarrhalis***

H. influenzae ***

H. parainfluenzae

a) Upper respiratory tract infections –

sinusitis due to:

* -lactamase producers

** intraphagocytic

7

Indications (Cont…)

GRAM-POSITIVE GRAM-NEGATIVE

S. pneumoniae

S. aureus ***

M. catarrhalis***

H. influenzae ***

H. parainfluenzae

K. pneumoniae*

E. coli*

b) Lower respiratory tract infections:

acute exacerbation of chronic bronchitis (AECB) due to:

* -lactamase producers

** intraphagocytic

8

c) Lower respiratory tract infections (cont):

Community acquired pneumonia (CAP) due to:

* -lactamase producers

** intraphagocytic

*** intracellular

Indications (Cont…)

GRAM-

POSITIVE

GRAM-

NEGATIVE

ATYPICAL

BACTERIA

S. pneumoniae

S. aureus ***

M. catarrhalis***

H. influenzae ***

H. parainfluenzae

K. pneumoniae*

E. coli*

M. pneumoniae ***

C. pneumoniae ***

L. pneumophila ***

10

e) Skin and soft tissue infections: uncomplicated infections such as abscess, cellulitis, carbuncles,

impetigo due to:

* -lactamase producers

** intra-phagocytic

Indications (Cont…)

GRAM-POSITIVE GRAM-NEGATIVE

S. aureus **

S. pyogenes

S. faecalis

Acinitobacter

Enterobacter

P. mirabilis

P. aeruginosa

E. coli*

K. pneumoniae*

11

f) Complicated skin and soft tissue infections

such as diabetic foot ulcers, pressure sores, traumatic and post-

surgical wound infections due to:

* -lactamase producers

** intra-phagocytic

Indications (Cont…)

GRAM-POSITIVE GRAM-NEGATIVE

S. aureus*

S. pyogenes

S. faecalis

P. mirabilis

E. coli*

K. pneumoniae*

Enterobacter

K. oxytoca

13

Dosage

500mg once daily, which enhances patient

compliance.

Bioequivalent Oral or IV , allows for switch

therapy.

Dosage and duration depends on the type and

severity of infection.

Continue for a further 48 - 72 hours after patient

is afebrile or evidence of bacteriological

eradication.

14

15